<div id="readability-page-1"><div> <div> , /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Atara Biotherapeutics, Inc. (&#34;Atara&#34; or the &#34;Company&#34;) (NASDAQ: ATRA). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATARA BIOTHERAPEUTICS, INC. (ATRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 22, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com. What Is The Lawsuit About? The complaint filed alleges that, between May 20, 2024 and January 9, 2026, Defendants failed to disclose to investors that: (1) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (2) accordingly, tabelecleucel's regulatory prospects were overstated; (3) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (4) all the foregoing was likely to have a significant negative impact on Atara's business and financial condition; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact: Howard G. Smith, Esq., Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Call us at: (215) 638-4847 Email us at: [email protected], Visit our website at: www.howardsmithlaw.com. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 [email protected] www.howardsmithlaw.com SOURCE Law Offices of Howard G. Smith <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE1Jk5ld3NJdGVtSWQ9UEg2MTA0OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTUxNTAwUFJfTkVXU19VU1BSX19fX19QSDYxMDQ5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE1Jk5ld3NJdGVtSWQ9UEg2MTA0OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTUxNTAwUFJfTkVXU19VU1BSX19fX19QSDYxMDQ5"/></div> </div></div>

ATRA

The Law Offices of Howard G. Smith announces that investors who suffered losses in Atara Biotherapeutics, Inc. (ATRA) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that the company misled investors regarding manufacturing issues and regulatory prospects between May 20, 2024, and January 9, 2026. Interested investors should contact the law firm before May 22, 2026, to participate.

prnewswire

Atara Biotherap

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

VG Health

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

ALPS Medical Breakthrough

iShares US Pharma

SPDR S&P Biotech

15:00 ETAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit